Rx IP Update - July 2017

Smart & Biggar
Contact

Smart & Biggar

Supreme Court of Canada strikes down "promise doctrine", upholds AstraZeneca’s NEXIUM patent as useful

As previously reported, on June 30, 2017, the Supreme Court of Canada granted AstraZeneca’s appeal in the NEXIUM (esomeprazole) patent infringement action against Apotex, rejecting the “promise doctrine” of utility as “not good law”, and thereby overturning the lower courts’ decisions that the patent was invalid: AstraZeneca Canada Inc v Apotex Inc (2017 SCC 36).


CETA Draft Regulations Published on Patent Linkage and Term Restoration

As previously reported, on July 15, 2017, the government published draft regulations regarding:

  1. changes to the Patented Medicines (Notice of Compliance) Regulations [“PMNOC Regulations”], and
  2. proposed Regulations to implement Certificates of Supplementary Protection (CSPs) [“CSP Regulations”] to compensate innovators for lost patent term due to regulatory delays.

The proposed changes to the PMNOC Regulations and the new CSP Regulations will herald a new environment for pharmaceutical companies, with long lasting impact. Representations may be made until July 30, 2017. Canada and the EU agreed to September 21, 2017 as the start date for the provisional application of CETA. The final amendments are therefore expected to be released before September 21, 2017.


Supreme Court of Canada dismisses Janssen’s application for leave to appeal FCA decision regarding administrative drug submissions

As reported previously, on October 12, 2016, the Federal Court of Appeal allowed four appeals relating to decisions by the Minister of Health to issue a notice of compliance (NOC) to Teva for exemestane tablets (a generic version of Pfizer’s AROMASIN) and an NOC to Hospira for INFLECTRA, an infliximab powder for solution (a biosimilar of Janssen’s REMICADE). The FCA found that the Minister was reasonable in finding that these cross-referenced drug submissions did not trigger section 5 of the PMNOC Regulations absent early working: Teva Canada Limited v Pfizer Canada Inc et al, 2016 FCA 248. Janssen’s application for leave to appeal the FCA decision was dismissed on June 22, 2017 (SCC Case No. 37342).


Health Canada News

Plain Language Labelling Regulations come into force for non-prescription drugs. On June 13, 2017, Health Canada issued a statement regarding the same-day coming into force of the Plain Language Labelling Regulations for non-prescription drug products. As reported previously, Health Canada has released a related guide: Good Label and Package Practices Guide for Non-prescription Drugs and Natural Health Products. As reported previously, the Plain Language Labelling Regulations for prescription products and those administered or obtained through a health professional have been in force since June 2015.

Proposed amendments to Food and Drug Regulations to warn patients about opioids. On June 17, 2017, proposed amendments to the Food and Drug Regulations were published that would allow the Minister of Health to add or amend terms and conditions to an authorization for opioid sales. The Minister of Health could then require the opioid authorization holder to implement a risk management program to identify, mitigate and monitor risks associated with opioid use. The amendments will also require a warning sticker and patient information handout accompany the sale of all prescription opioids. Comments may be provided until August 31, 2017. In the news release announcing the amendments, Health Canada stated that “[w]hen finalized, this will be the first time that the Government of Canada will use the power granted by Vanessa’s Law to apply terms and conditions.”

Health Canada publishes regulations permitting importation of drugs for an urgent public health need. As previously reported, Health Canada proposed amendments to the Food and Drug Regulations that would provide for importation and use of drugs authorized for sale in the United States, European Union or Switzerland to meet an urgent public health need. As announced in a news release, the amended Regulations were released on June 20, 2017 and an initial list of drugs (covering certain drugs for the treatment of opioid dependence and tuberculosis) was also published. By this regulatory pathway (see description here), public health officials in a jurisdiction may seek access to a drug and its addition to the list by notifying Health Canada of an urgent public health need for the drug within their jurisdictions.

Consultation on possible changes to generic drug equivalence under the Food and Drug Regulations. Health Canada is soliciting comments (until October 13, 2017) regarding possible changes to the Food and Drug Regulations relating to establishing pharmaceutical equivalence between a proposed generic drug product and a Canadian Reference Product (CRP)(see Consultation document here).Under the proposed changes, a notice of compliance constituting a “declaration of therapeutic equivalence” to a CRP could be issued to a generic product when the generic product and CRP are “pharmaceutical equivalents” (same medicinal ingredient in same dosage form) or “pharmaceutical alternatives” (different salts, esters or complexes of the medicinal ingredient, and/or different but comparable dosage forms to the CRP), if the generic for which bioequivalence has been demonstrated has the same route of administration and the same safety and effectiveness as the CRP. The Regulations currently define “pharmaceutical equivalent” as “a new drug that, in comparison with another drug, contains identical amounts of the identical medicinal ingredients, in comparable dosage forms, but that does not necessarily contain the same non-medicinal ingredients”. Health Canada’s current interpretation of “identical medicinal ingredient” is set out in its 2003 policy and 2015 interim supplemental policy (as previously reported). The proposed changes would also define “medicinal ingredient” as the active substance that contains the therapeutic moiety in the drug product that is administered or consumed, rather than the starting active pharmaceutical ingredient/input material.


CADTH consultation regarding proposal to allow revisions to CDEC recommendations

CADTH is seeking feedback until August 11, 2017 on a proposal to permit revisions, during the therapeutic review process, to existing Canadian Drug Expert Committee (CDEC) recommendations made through the Common Drug Review (CDR) process, eliminating the need to update recommendations through the request for advice process. During the therapeutic review process, CDEC will consider whether any recommendations should be revised. Manufacturers will be notified at the stage of initial therapeutic review of any recommendation that is being revised, the rationale, as well as the revised reimbursement criteria and/or conditions. There will be no embargo period. A formal reconsideration process will not be available, but manufacturers may provide stakeholder feedback. Their input will be considered prior to finalizing the revised recommendations, which will occur at the meeting to finalize the therapeutic review recommendations.


PMNOC proceedings

Medicine:

silodosin (RAPAFLO)

Applicants:

Allergan Pharma Co, Allergan Inc and Kissei Pharmaceutical Co, Ltd

Respondents:

The Minister of Health and Apotex Inc

Date Commenced:

June 9, 2017

Court File No.:

T-830-17

Comment:

Application for Order of prohibition until expiry of Patent No. 2,496,780. Apotex alleges non-infringement.

Medicine:

silodosin (RAPAFLO)

Applicants:

Allergan Pharma Co, Allergan Inc and Kissei Pharmaceutical Co, Ltd.

Respondents:

The Minister of Health and Apotex Inc

Date Commenced:

June 9, 2017

Court File No.:

T-831-17

Comment:

Application for Order of prohibition until expiry of Patent No. 2,507,002. Apotex alleges non-infringement.

Medicine:

metformin hydrochloride (GLUMETZA)

Applicants:

Valeant Canada LP/Valeant Canada SEC

Respondents:

Generic Partners Canada Inc and the Minister of Health

Respondent/Patentee:

Depomed, Inc

Date Commenced:

June 9, 2017

Court File No.:

T-834-17

Comment:

Application for Order of prohibition until expiry of Patent No. 2,412,671. Generic Partners alleges non-infringement and invalidity.

Medicine:

metformin hydrochloride (GLUMETZA)

Applicants:

Valeant Canada LP/Valeant Canada SEC

Respondents:

Generic Partners Canada Inc and the Minister of Health

Respondent/Patentee:

Valeant Pharmaceuticals Luxembourg Sàrl

Date Commenced:

June 9, 2017

Court File No.:

T-835-17

Comment:

Application for Order of prohibition until expiry of Patent No. 2,476,496. Generic Partners alleges non-infringement and invalidity.

Other Proceedings

Medicine:

oxycodone hydrochloride (OxyNEO)

Plaintiffs:

Purdue Pharma and Euro-Celtique SA

Defendant:

Collegium Pharmaceutical, Inc

Date Commenced:

June 13, 2017

Court File No.:

T-856-17

Comment:

Infringement action regarding Patent No. 2,557,845.

Medicine:

trastuzumab (HERCEPTIN)

Plaintiff:

Pfizer Canada Inc

Defendant:

Genentech, Inc

Date Commenced:

June 14, 2017

Court File No.:

T-869-17

Comment:

Action seeking a declaration of invalidity and non-infringement of Patent No. 2,407,556.

Medicine:

trastuzumab (HERCEPTIN)

Plaintiff:

Pfizer Canada Inc

Defendant:

Genentech, Inc

Date Commenced:

June 15, 2017

Court File No.:

T-876-17

Comment:

Action seeking a declaration of invalidity and non-infringement of Patent No. 2,540,547.

To check the status of Federal Court cases, please click here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar
Contact
more
less

Smart & Biggar on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.